Zelquistinel in the Treatment of Major Depressive Disorder (AGN-241751)
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of AGN-241751 in Adult Participants With Major Depressive Disorder
Sponsor: Syndeio Biosciences, Inc
Listed as NCT03586427, this observational or N/A phase trial focuses on Depressive Disorder, Major and remains completed. Sponsored by Syndeio Biosciences, Inc, it has been updated 17 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Apr 28, 2026 — Present [daily]
Completed
Phase: PHASE2 → None
-
Sep 2025 — Apr 2026 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 12 earlier versions
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Sep 2019 — Aug 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
Contact Information
- Syndeio Biosciences, Inc
For direct contact, visit the study record on ClinicalTrials.gov .